EUVIMEDSkopri EUVIMED
Open access · CC BY-NC 4.0

Longitudinal Relationship Between Elevated Liver Biochemical Tests and Negative Clinical Outcomes in Primary Biliary Cholangitis: A Population‐Based Study

Kris V Kowdley, David W Victor, Joanna P MacEwan, Radhika Nair, Alina Levine, Jennifer Hernandez, Leona Bessonova, Jing Li, Darren Wheeler, Gideon Hirschfield iD

Alimentary Pharmacology & Therapeutics · 2025-06 · 61 (11) · 1775-1784

DOI: 10.1111/apt.70120 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, published online on 2025-04-02. Written by Kris V Kowdley and 9 co-authors. Institution: Liver Institute Northwest and Elson S. Floyd College of Medicine, Washington State University, Seattle, Washington, USA. Major MEDLINE topics: Liver Cirrhosis, Biliary, Alkaline Phosphatase. Cited 13 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Intercept Pharmaceuticals.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Elevated liver biochemistries are associated with increased risk of negative outcomes in patients with primary biliary cholangitis (PBC).

Aims

To evaluate whether longitudinal monitoring of liver biochemistries and fibrosis scores provides additional prognostic value and to assess the relationship between the degree of elevation of multiple biomarkers within different alkaline phosphatase (ALP) strata.

Methods

Adults with PBC were identified from Komodo's Healthcare Map. A Cox proportional hazards model examined time to first occurrence of hospitalisation due to hepatic decompensation, liver transplantation, or death as a function of the proportion of time during follow‐up that liver biochemistries and fibrosis scores exceeded thresholds. Within ALP strata (ALP ≤ upper limit of normal [ULN]; ALP>ULN to ≤ 1.67 × ULN; ALP > 1.67 × ULN), separate multivariate Cox hazard models assessed the association between time‐varying covariates and the composite endpoint.

Results

Overall, 3974 patients were included; 88.2% were female, with a mean age of 59.4 years. The median follow‐up was 2.5 years. Increasing magnitude and duration beyond established thresholds of ALP, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TB), AST/platelet ratio index (APRI) and fibrosis‐4 (FIB‐4) were associated with increased risk of negative outcomes. Elevated ALT, AST, TB, APRI and FIB‐4 were associated with increased risk of negative outcomes across all ALP strata.

Conclusions

Prolonged elevation of multiple hepatic biomarkers and fibrosis scores is associated with a greater risk of negative clinical outcomes, underscoring the importance of ongoing monitoring beyond the guideline‐recommended initial treatment response to guide timely treatment decisions and improve PBC management.

Subjects

MeSH terms (MEDLINE)

Liver Cirrhosis, BiliaryAlkaline PhosphataseHumansFemaleMaleMiddle AgedBiomarkersAgedLongitudinal StudiesLiver Function TestsProportional Hazards ModelsAspartate AminotransferasesPrognosisAlanine TransaminaseAdult

Author keywords

clinical outcomeshepatic failureliver function testprimary biliary cholangitisrisk factor

Substances

BiomarkersAlkaline PhosphataseAspartate AminotransferasesAlanine Transaminase

Authors and institutions

  • Liver Institute Northwest and Elson S. Floyd College of Medicine, Washington State University, Seattle, Washington, USA.
  • Houston Methodist Hospital, Houston, Texas, USA.
  • Genesis Research Group, Hoboken, New Jersey, USA.
  • Intercept Pharmaceuticals, Morristown, New Jersey, USA.
  • The Autoimmune and Rare Liver Disease Programme, Division of Gastroenterology and Hepatology, Toronto General Hospital, Toronto, Ontario, Canada.

ORCID profiles: Gideon Hirschfield

Funding

  • Intercept Pharmaceuticals

Cite

APA

Kowdley, K. V., Victor, D. W., MacEwan, J. P., Nair, R., Levine, A., Hernandez, J., Bessonova, L., Li, J., Wheeler, D., & Hirschfield, G. (2025). Longitudinal Relationship Between Elevated Liver Biochemical Tests and Negative Clinical Outcomes in Primary Biliary Cholangitis: A Population‐Based Study. Alimentary Pharmacology & Therapeutics, 61(11), 1775-1784. https://doi.org/10.1111/apt.70120

Vancouver

Kowdley KV, Victor DW, MacEwan JP, Nair R, Levine A, Hernandez J, et al. Longitudinal Relationship Between Elevated Liver Biochemical Tests and Negative Clinical Outcomes in Primary Biliary Cholangitis: A Population‐Based Study. Alimentary Pharmacology & Therapeutics. 2025;61(11):1775-1784. doi:10.1111/apt.70120

BibTeX
@article{Kowdley2025,
  author = {Kowdley, Kris V and Victor, David W and MacEwan, Joanna P and Nair, Radhika and Levine, Alina and Hernandez, Jennifer and Bessonova, Leona and Li, Jing and Wheeler, Darren and Hirschfield, Gideon},
  title = {Longitudinal Relationship Between Elevated Liver Biochemical Tests and Negative Clinical Outcomes in Primary Biliary Cholangitis: A Population‐Based Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  volume = {61},
  number = {11},
  pages = {1775--1784},
  doi = {10.1111/apt.70120}
}
Start for free →